| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR + and ALK + Positive Non–small-cell Lung Cancer Treated in the Real-World
|
Goulart, Bernardo H.L.
|
|
|
22 |
5 |
p. e723-e733
|
artikel
|
| 2 |
Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V600-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations
|
Metzenmacher, Martin
|
|
|
22 |
5 |
p. e668-e672
|
artikel
|
| 3 |
ALK Rearrangement in Lung Neuroendocrine Neoplasms: Case Series of Non-Asian Patients With Response to ALK Inhibitors
|
Doubre, Helene
|
|
|
22 |
5 |
p. e686-e690
|
artikel
|
| 4 |
Biomarkers of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer: Beyond PD-L1
|
Cabezón-Gutiérrez, Luis
|
|
|
22 |
5 |
p. 381-389
|
artikel
|
| 5 |
Corrigendum to ‘Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities’
|
Begnaud, Abbie
|
|
|
22 |
5 |
p. e793
|
artikel
|
| 6 |
Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report
|
Harada, Guilherme
|
|
|
22 |
5 |
p. e708-e711
|
artikel
|
| 7 |
Editorial Board
|
|
|
|
22 |
5 |
p. A1
|
artikel
|
| 8 |
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies
|
Weiss, Jared
|
|
|
22 |
5 |
p. 449-460
|
artikel
|
| 9 |
Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation
|
Lin, Gengpeng
|
|
|
22 |
5 |
p. e712-e715
|
artikel
|
| 10 |
Extra-axial Chordoma Masquerading as Lung Cancer
|
Ball, Somedeb
|
|
|
22 |
5 |
p. e658
|
artikel
|
| 11 |
Immunotherapy and Stereotactic Ablative Radiotherapy for Lung Cancer with Co-existing Interstitial Lung Disease: A Case Report
|
Li, George J.
|
|
|
22 |
5 |
p. e734-e737
|
artikel
|
| 12 |
Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non–Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy
|
Liu, Jason
|
|
|
22 |
5 |
p. e678-e683
|
artikel
|
| 13 |
Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non–Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab
|
Shintani, Takashi
|
|
|
22 |
5 |
p. 401-410
|
artikel
|
| 14 |
Letter to the Editor Regarding “Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy”
|
Satoh, Hiroaki
|
|
|
22 |
5 |
p. e782
|
artikel
|
| 15 |
Lobe-specific Lymph Node Dissection for Clinical Stage IA Non–small-cell Lung Cancer: What do we know?
|
Peng, Lei
|
|
|
22 |
5 |
p. 478-479
|
artikel
|
| 16 |
Lung Cancer and Granuloma Identification Using a Deep Learning Model to Extract 3-Dimensional Radiomics Features in CT Imaging
|
Lin, Xiaofeng
|
|
|
22 |
5 |
p. e756-e766
|
artikel
|
| 17 |
Lung Resection Without Tissue Diagnosis: A Pragmatic Perspective on the Indeterminate Pulmonary Nodule
|
Giles, Andrew E.
|
|
|
22 |
5 |
p. e774-e781
|
artikel
|
| 18 |
Management of Cutaneous Immunotherapy Toxicities
|
Altan, Mehmet
|
|
|
22 |
5 |
p. e783
|
artikel
|
| 19 |
Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors
|
Lim, Jeong Uk
|
|
|
22 |
5 |
p. e786-e792
|
artikel
|
| 20 |
NF1-Mutant Cancer and Immune Checkpoint Inhibitors: A Large Database Analysis
|
Li, Xuanzong
|
|
|
22 |
5 |
p. 480-481
|
artikel
|
| 21 |
Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone
|
Takao, Tomoaki
|
|
|
22 |
5 |
p. e784-e785
|
artikel
|
| 22 |
Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series
|
Dobre, Ioana A.
|
|
|
22 |
5 |
p. e738-e744
|
artikel
|
| 23 |
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
|
Dall'Olio, Filippo G.
|
|
|
22 |
5 |
p. 423-431
|
artikel
|
| 24 |
Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids
|
Frost, Nikolaj
|
|
|
22 |
5 |
p. 411-422
|
artikel
|
| 25 |
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial
|
Leonetti, Alessandro
|
|
|
22 |
5 |
p. 473-477
|
artikel
|
| 26 |
Precision Treatment of Advanced Lung Adenocarcinoma With Coexisting EGFR, ALK, and ROS1 Mutations: A Case Report
|
Zhang, Yaping
|
|
|
22 |
5 |
p. e699-e702
|
artikel
|
| 27 |
Predictors of In-Hospital Death in Patients with Lung Cancer Admitted for Acute Radiation Pneumonitis: A Healthcare Cost and Utilization Project (HCUP) Analysis
|
Kirkland, R. Spencer
|
|
|
22 |
5 |
p. e716-e722
|
artikel
|
| 28 |
Prognostic Value of Computed Tomography and/or 18F-Fluorodeoxyglucose Positron Emission Tomography Radiomics Features in Locally Advanced Non-small Cell Lung Cancer
|
Moran, Angel
|
|
|
22 |
5 |
p. 461-468
|
artikel
|
| 29 |
Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma
|
Davis, Alexander
|
|
|
22 |
5 |
p. e665-e667
|
artikel
|
| 30 |
Racial Disparities in Overall Survival and Surgical Treatment for Early Stage Lung Cancer by Facility Type
|
Merritt, Robert E
|
|
|
22 |
5 |
p. e691-e698
|
artikel
|
| 31 |
RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection
|
Basse, C.
|
|
|
22 |
5 |
p. 469-472
|
artikel
|
| 32 |
Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non–small-cell Lung Cancer
|
Boyce-Fappiano, David
|
|
|
22 |
5 |
p. e745-e755
|
artikel
|
| 33 |
STK11/LKB1 Mutation-positive Primary Thymic Mucinous Adenocarcinoma Accompanied by Cerebellar Metastasis: A Case Report and Literature Review
|
Himuro, Naoya
|
|
|
22 |
5 |
p. e659-e664
|
artikel
|
| 34 |
Systemic Inflammatory Markers of Survival in Epidermal Growth Factor–Mutated Non–Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis
|
Chan, Sze Wah Samuel
|
|
|
22 |
5 |
p. 390-407
|
artikel
|
| 35 |
Table of Contents
|
|
|
|
22 |
5 |
p. A2-A7
|
artikel
|
| 36 |
Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report
|
Aredo, Jacqueline V.
|
|
|
22 |
5 |
p. e673-e677
|
artikel
|
| 37 |
The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC
|
Perna, Marco
|
|
|
22 |
5 |
p. e767-e773
|
artikel
|
| 38 |
Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report
|
Waddington, Thomas
|
|
|
22 |
5 |
p. e703-e707
|
artikel
|
| 39 |
The Role of Stereotactic Body Radiation Therapy for Pulmonary Carcinosarcoma
|
Huang, Wei-Lun
|
|
|
22 |
5 |
p. e684-e685
|
artikel
|
| 40 |
The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression
|
Vekens, Karolien
|
|
|
22 |
5 |
p. 432-440
|
artikel
|
| 41 |
Three Decades of Malignant Pleural Mesothelioma: An Academic Center Experience
|
Nasser, Abdullah
|
|
|
22 |
5 |
p. 441-448
|
artikel
|
| 42 |
Where Is the Primary Site of the Extra-Axial Chordoma Masquerading As Lung Cancer?
|
Kikuchi, Yoshinao
|
|
|
22 |
5 |
p. e655-e657
|
artikel
|
Tijdschrift beschrijving